Raymond James & Associates’s Ocugen OCGN Stock Holding History

Raymond James & Associates’s Portfolio OCGN Stock Details OCGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,100	Closed	-$29.7K	–	4050
2024 Q1	$29.7K	Buy	+18,100	New	+$15.2K	﹤0.01%	3845

Other funds holding OCGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Raymond James & Associates's OCGN Position: Q2 2024 in Review

Raymond James & Associates sold out of Ocugen (OCGN) in Q2 2024, closing a stake of 18,100 shares — an estimated $29.7K sold.

Raymond James & Associates first reported a position in OCGN in Q1 2024 and held it in 1 quarter. The position peaked at $29.7K in Q1 2024. 101 funds tracked by Wall St. Rank hold OCGN as of Q2 2024.

Raymond James & Associates reported no remaining Ocugen position as of Q2 2024 after selling out during the quarter.
Raymond James & Associates sold 18,100 Ocugen shares in Q2 2024, an estimated $29.7K.
Raymond James & Associates first reported a position in Ocugen in Q1 2024 and held it in 1 quarter.
Raymond James & Associates's Ocugen position peaked at $29.7K in Q1 2024.
101 funds tracked by Wall St. Rank held Ocugen as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.